Pristaĭko Ia I, Feshchenko Iu I, Opanasenko N S
Institut ftiziatrii i pul'monologii im. F.G. Ianovskogo AMN Ukrainy, g. Kiev.
Klin Khir. 1997(5-6):24-5.
Klaforan pharmacodynamics was studied up in pleural exudate and blood serum of the patients with purulent-destructive pulmonary diseases after its single endolymphatic and intravenous introduction in the dose 60 mg/kg of the body mass. Convalescence frequency in control group was 61.6%, in principal-82.9%, lethality-18.6 and 9.3% accordingly.
在体重为60mg/kg的患者单次经内淋巴和静脉注射后，对患有化脓性破坏性肺病的患者的胸腔积液和血清中的头孢克洛药效学进行了研究。对照组的康复频率分别为61.6%、主要组为82.9%，致死率分别为18.6%和9.3%。
